Hon Dr MEGAN WOODS: New Zealand's science and vaccine manufacturing sectors have an incredibly important role to play in ensuring New Zealanders get early access to a vaccine. Locally, the Vaccine Alliance Aotearoa New Zealand will receive $10 million to lead COVID-19 vaccine research through a vaccine development and evaluation platform. This will see the brightest minds from the Malaghan Institute of Medical Research, the University of Otago, and Victoria University of Wellington work together to support global efforts to develop vaccines that are safe and fit for purpose. BioCell will receive $3 million to upgrade its existing facilities so it's in a position to scale up and support local and global vaccine manufacturing. Depending on the chosen vaccine, this could see up to 100 million vaccines manufactured annually right here in New Zealand—an important contribution to the global effort. New Zealand is well placed through the efforts of our researchers and Medsafe to leverage our expertise and to ensure that everybody can access a safe and effective vaccine as soon as possible. 